MGRX vs NXGL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MGRX exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -1576.40%. Despite a low Price-to-Book ratio of 0.35, the company is experiencing consistent revenue contraction (-10.30% YoY) and massive long-term value destruction, with a 5-year price decline of 99.3%. The lack of analyst coverage and bearish insider activity further signal a lack of confidence in the company's viability.
NXGL exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company suffers from chronic profitability issues, with negative operating margins (-43.42%) and a consistent track record of missing earnings estimates (0/4 beats in the last year). Revenue is shrinking both YoY and Q/Q, while the stock has plummeted over 73% in the last year. Combined with bearish insider selling by the CEO, the outlook is highly precarious.
Compare Another Pair
Related Comparisons
MGRX vs NXGL: Head-to-Head Comparison
This page compares Mangoceuticals, Inc. (MGRX) and NEXGEL, Inc. (NXGL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.